InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (64 ops.)
Discover the full record of transactions filed by MAETZOLD DEREK J, Founder, President and Chief Executive Officer. Director active across 1 companies, notably Castle Biosciences INC. Aggregated, 71 filings have been published. Total volume traded: €8.6m. The latest transaction was filed on 10 January 2022 (Don). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations71 total
22,311 shares
Common Stock
SEC:0001447362-22-000068:0·
0122,181 shares0
Common Stock
SEC:0001447362-22-000018:0·
0122,181 shares0
Common Stock
SEC:0001447362-22-000018·
5,363 shares
Common Stock
SEC:0001447362-21-000266·
5,363 shares
Common Stock
SEC:0001447362-21-000266:0·
€33,84016,406 shares@ €2.06260.0029% mcap0.8% of flow
Common Stock
SEC:0001447362-21-000259·
€33,84016,406 shares@ €2.06260.0029% mcap0.4% of flow
Common Stock
SEC:0001447362-21-000259:0·
€20,696433 shares@ €47.7970.0018% mcap0.5% of flow
Common Stock
SEC:0001447362-21-000257·
€20,696433 shares@ €47.7970.0018% mcap0.2% of flow
Common Stock
SEC:0001447362-21-000257:0·
€32,258600 shares@ €53.76270.0028% mcap0.7% of flow
Common Stock
SEC:0001447362-21-000245·
€32,258600 shares@ €53.76270.0028% mcap0.4% of flow
Common Stock
SEC:0001447362-21-000245:0·
€7,562133 shares@ €56.85370.0007% mcap0.2% of flow
Common Stock
SEC:0001447362-21-000241·
€7,562133 shares@ €56.85370.0007% mcap0.1% of flow
Common Stock
SEC:0001447362-21-000241:0·
€28,077511 shares@ €54.94420.0024% mcap0.6% of flow
Common Stock
SEC:0001447362-21-000237·
€28,077511 shares@ €54.94420.0024% mcap0.3% of flow
Common Stock
SEC:0001447362-21-000237:0·
€25,723496 shares@ €51.86150.0022% mcap0.6% of flow
Common Stock
SEC:0001447362-21-000233·
€25,723496 shares@ €51.86150.0022% mcap0.3% of flow
Common Stock
SEC:0001447362-21-000233:0·
€159,2772,831 shares@ €56.26170.014% mcap3.7% of flow
Common Stock
SEC:0001447362-21-000231·
€159,2772,831 shares@ €56.26170.014% mcap1.8% of flow
Common Stock
SEC:0001447362-21-000231:0·
€176,0303,115 shares@ €56.51040.015% mcap4.0% of flow
Common Stock
SEC:0001447362-21-000229·
€176,0303,115 shares@ €56.51040.015% mcap2.0% of flow
Common Stock
SEC:0001447362-21-000229:0·
€59,410958 shares@ €62.01440.0051% mcap1.4% of flow
Common Stock
SEC:0001447362-21-000223·
€59,410958 shares@ €62.01440.0051% mcap0.7% of flow
Common Stock
SEC:0001447362-21-000223:0·
€48,533781 shares@ €62.14240.0042% mcap1.1% of flow
Common Stock
SEC:0001447362-21-000221·
€59,8071,000 shares@ €59.80720.0052% mcap1.4% of flow
Common Stock
SEC:0001447362-21-000219·
25 of 71 declarations
About MAETZOLD DEREK J
Derek J. Maetzold is the founder of Castle Biosciences, a company he established in September 2007 and has led ever since as President, Chief Executive Officer, and a member of the board of directors. In that role, he serves as the company’s principal executive leader, guiding strategy, operations, and long-term growth for a U.S.-listed diagnostics business. Castle Biosciences has described his founding vision as improving care for patients with rare cancers by developing innovative tests that help clinicians make more informed treatment decisions. Under his leadership, the company has built a portfolio focused on specialty diagnostic and prognostic solutions, including tests used in skin cancers, Barrett’s esophagus, and uveal melanoma. Before founding Castle Biosciences, Mr. Maetzold held leadership positions at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals, and Sandoz Pharmaceuticals (now part of Novartis). This background gave him broad experience across pharmaceuticals, life sciences, and healthcare innovation, with exposure to commercialization, technology development, and operational leadership. Castle Biosciences notes that he has contributed to the discovery, development, and commercialization of five diagnostic and prognostic cancer tests, has co-authored multiple scientific publications, and is a co-inventor of several technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold also serves as a director of PreludeDx and IMPACT Melanoma, underscoring his involvement in broader healthcare and mission-driven organizations. His profile combines entrepreneurial leadership with scientific and commercial expertise, making him a notable executive in precision diagnostics. He earned a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and in the MBA program at the University of California, Riverside. Overall, his career reflects sustained leadership in translating scientific innovation into clinically useful diagnostic products and building organizations around patient-centered healthcare solutions.
